To accelerate development and launch of effective drugs in the Russian market Russian pharma company VERTEX and Federal State Budgetary Institution North Western Federal Medical Research Center (NWFMRC) named after V.A. Almazov, Russian Ministry of Health, signed an agreement on scientific cooperation.
Joint project of the production facility and scientific healthcare institution opens wide horizons in the field of development and conduct of preclinical, clinical, pharmacoeconomic studies of drugs. It will be possible to conduct preclinical studies in animals and clinical studies in humans at one spot, which is very convenient. A next generation center of preclinical translation studies is under construction. It will be part of organization of V.A. Almazov NWFMRC. It will be possible to conduct works in cell cultures.
At the VERTEX Center it is planned to perform preclinical and clinical trials of novel quazi-original drugs in the field of cardiology, i.e. wit original pharmaceutical forms, original dosages and modes of action of the active substance in the human body. Phase II clinical trials of original drug VERTEX for neurological indications may be started in 2017 at the Center. Specialized studies of other drugs are considered over a longer perspective.